ANZCTR search results

This project will test a new intervention that aims to prevent people's social media use from causing them to feel dissatisfied with their body and experience disordered eating. The intervention uses exercises designed to help people reduce their self-criticism and increase their self-compassion when using social media. The project will assess how much participants engage with the intervention, request their feedback on it, and determine whether there is evidence that it may help to prevent disordered eating. Because this intervention has not been tested before, we do not know if it will be effective or acceptable, but we hope that it will reduce appearance comparison, self-criticism, and disordered eating, and increase body image flexibility.

The aim of this study is to evaluate the state-wide dissemination of the RT for Teens program, This revised intervention was previously evaluated via cluster RCT in 16 secondary schools (ACTRN12615000360516; Kennedy et al., 2018). This trial saw improvements in students' muscular fitness, resistance training skill competency and resistance training self-efficacy. To improve the health behaviours of NSW students, the program was then delivered across the state. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework was be utilised to evaluate the program. We hypothesis that the modified, flexible design of the RT for Teens program will maximise adoption and implementation potential in schools, leading to enhanced program reach - whilst still effectively improving student outcomes as in the RCT. Citation: Kennedy, S. G., Smith, J. J., Morgan, P. J., Peralta, L. R., Hilland, T. A., Eather, N., ... & Lubans, D. R. (2018). Implementing resistance training in secondary schools: a cluster randomized controlled trial. Medicine & Science in Sports & Exercise, 50(1), 62-72.

The study will be a multi-center, open-label, single-dose, parallel-arm evaluation of the ocular effect and safety of NVK031 in healthy volunteers with brown eyes and non-brown eyes. In this study, four test products of NVK031 will be evaluated. Approximately 44 eligible subjects will be healthy volunteers who are 18 to 55 years old and free of clinically significant ocular pathology. The primary objectives are to identify a MED and to assess the overall effect of NVK031 on the change from baseline (pre-dose at Visit 2) in mesopic pupil diameter for subjects receiving the MED.

The primary aim of this study is to determine whether peripheral blood flow differs according to the approach used to prescribe training pressures for blood flow restricted exercise (BFRE). A secondary aim is to explore associations between self-reported tolerability and cuff pressures. The specific research questions posed for this study of older adults are: 1) Does peripheral blood flow rate after cycling differ between cuff pressure prescription approaches? 2) Are sensations of discomfort, breathlessness and tightness intensity related to cuff pressure? We hypothesise that in older adults: 1) Peripheral blood flow rate will be significantly lower when the cuff is inflated and higher following cuff release when percent of systolic blood pressure, perceived cuff tightness or an arbitrary pressure are compared to the recommended percent of limb occlusion pressure (LOP) approach for prescribing blood flow restricted training pressure. 2) Significant positive associations will exist between cuff pressures and a) sensations of peripheral muscle discomfort and tightness under the cuff during cuff occlusion and b) intensity of breathing discomfort upon cuff release.

The proposed study aims to answer an important clinical question: can subthreshold psychotic manifestations be effectively treated with cannabidiol (CBD), a non-psychoactive compound of the plant Cannabis sativa? The question has taken on increased clinical importance in the wake of recent evidence questioning the need and efficacy of specific interventions in the UHR group. This study will test CBD for the first time in the UHR phase of psychotic disorder.

Behavioural eHealth and mHealth interventions have been moderately successful in increasing physical activity. Therefore, there is still room for further improvement. Chatbots equipped with natural language processing can effectively interact and engage with users. Chatbots can also help continuously self-monitor physical activity levels using data from wearable body sensors and smartphones. However, there is lack of studies evaluating effectiveness of chatbot interventions on physical activity. The aim of this study was to investigate the feasibility, acceptability and effectiveness of an interactive machine learning based chatbot that uses natural language processing and adaptive goal setting to improve physical activity among inactive adults living in Australia.

Over 400,000 community and hospital patients in Australia have chronic wounds, posing an estimated annual burden of $3 billion in treatment costs. These patients risk longer hospital stays and 30-day readmission as a result of wound complications. Pressure injuries (PI) and lower leg ulcers, are the most common chronic wounds, with PI accounting for 84% of chronic wounds. With COVID-19, use of telehealth consultations is a timely intervention for patients with chronic wounds. However, research in this area is scarce. This translational research study will determine the efficacy of the Virtual wound Care command Centre (VATICAN) in four settings and three health districts. The project will reduce face-to-face visits between staff and patients, promote timely clinical intervention and prevent deterioration of wounds necessitating re-admission, thereby alleviating demand on services. This application, through leveraging off an existing pilot study, provides the opportunity to test a virtual wound care model, enhancing transferability and scalability.

This double-blinded, randomised controlled trial aims to determine the feasibility, tolerability, and safety of intermittent theta burst stimulation (iTBS) and oral ketamine (OK) as a combination treatment for PTSD. Given the complexity and broad range of symptom presentations in patients diagnosed with PTSD, this study seeks to capture changes in sleep quality, perceived stress, suicidality, depression, anhedonia, chronic pain, and social/occupational functioning. Findings from this study will help to identify the brain circuitry involved with and neural processes associated with these glutamatergic and GABAergic-based interventions.

This study will investigate the efficacy of an eHealth nutrition intervention on lifestyle-related colorectal cancer risk in patients undergoing colonoscopy Who is it for? You may be eligible to join this study if you are aged 18 and above, scheduled to have a colonoscopy done by participating surgeons at the Open Access Colonoscopy service at the Newcastle Endoscopy Clinic and the Direct Access Colonoscopy service at John Hunter Hospital and Belmont Hospital and have access to a computer, tablet or smartphone with internet access. Study details Participants in this study are randomly allocated (by chance) to one of three groups. Participants in group one will receive an enhanced nutrition intervention consisting of a 30 minute online consultation via Zoom with a Dietitian, and a personal nutrition report. Participants in group two will receive, via email, a personal nutrition report. While participants in group three will not receive any intervention materials or education during the active intervention period. After completing the 3 month assessment, participants in group three will receive their personal nutrition report. Colorectal cancer risk will be assessed using the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) score. Feasibility and acceptability of the intervention will be assessed using a number of different surveys. It is hoped that this research project will provide new knowledge about the efficacy of an eHealth nutrition intervention at reducing lifestyle-related colorectal cancer risk in adults.

Every day, more than one million people globally are diagnosed with the four most common non-viral sexually transmitted infections (STIs) and gonorrhoea and chlamydia are the two most common bacterial STIs. In Australia, rates are at increasing rapidly with their highest levels in recent years. Infections in women can cause infertility, and in both sexes, increase HIV acquisition and transmission. Treatment failure is an increasing issue and may be due to factors related to the bacteria (e.g. antibiotic resistance), the individual (e.g. immune response, vomiting/diarrhoea) or how the body processes the drug (its ‘pharmacokinetics’, or PK). Antibiotic resistance for STIs has developed so rapidly that in 2017, the World Health Organization (WHO) declared resistant gonorrhoea as an urgent global threat with the real danger that it may soon be untreatable. We now know that treatment failures occur more often at non-genital (‘extra-genital’) sites such as the mouth or rectum, with current treatment cure for chlamydia or gonorrhoea being up to 20% lower than at the genital site. We also know the mouth/oropharynx drives STI transmission through oral sex, kissing and use of saliva during sex so effective treatments for non-genital infections are critical to stop ongoing transmission. Rectal infections in women can result in persisting vaginal infection from cross contamination between the two sites. There are only a few new drugs in development to treat STIs, but they are many years away and may not be sufficiently effective, especially not for the mouth/oropharynx. Therefore, clinicians must optimise what drugs we have now, but without clinical trial evidence, they must rely on pharmacokinetic (PK) data to guide this decision making. However, there are few PK data available for the mouth or rectum. This project will develop innovative techniques to generate the first comprehensive data in the mouth and rectum for four commonly used antibiotics used to treat STIs – cefixime, ceftriaxone, ciprofloxacin, azithromycin and doxycycline. After this we will apply these methods to emerging drugs currently being tested in trials that have not been marketed yet. This is to ensure new drugs in the pipeline will be effective against STIs. These data will address the urgent global call for data to inform STI treatment guidelines.